Shares of Intellia Therapeutics NTLA have plunged 55.2% over the past three months.The steep decline follows a significant ...

Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders (or potential shareholders) will be happy to see that ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more clinical ...

Intellia Therapeutics has a promising candidate about to enter late-stage testing. The company has a couple of exciting earlier-stage programs, too. Despite recent progress, the biotech remains risky.

Reports indicate that ARK Invest funds purchased roughly 236,000 additional shares of Intellia in early 2026. These acquisitions occurred as the stock traded near its 52-week lows, under significant ...

When short sellers are betting heavily against a company, shareholders should exercise caution. At the top of the list is ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of the ...

Thursday was hardly a good day to be a shareholder of Intellia Therapeutics (NASDAQ: NTLA). After the biotech delivered some news from the lab and witnessed one analyst's negative reaction to it, the ...

Wall Street analysts have high hopes for Intellia Therapeutics stock. The company's late-stage pipeline programs are shaping up nicely. Upcoming data readouts will need to be very impressive to hit ...